Swiss Life Asset Management Ltd Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Swiss Life Asset Management Ltd grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 112.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,658 shares of the biopharmaceutical company’s stock after purchasing an additional 12,500 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $13,302,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $34,000. Traub Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at about $38,000. Finally, Berbice Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6%

NASDAQ:REGN opened at $732.87 on Friday. The company has a market capitalization of $77.48 billion, a PE ratio of 17.63, a P/E/G ratio of 1.98 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock’s 50 day moving average price is $765.35 and its 200 day moving average price is $699.83. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company earned $12.07 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Analysts Set New Price Targets

A number of research firms have weighed in on REGN. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Guggenheim increased their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a report on Monday, February 9th. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Finally, HSBC started coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.